nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—breast cancer	0.524	1	CbGaD
Tafluprost—PTGFR—corpus luteum—breast cancer	0.0731	0.558	CbGeAlD
Tafluprost—PTGFR—nipple—breast cancer	0.00937	0.0715	CbGeAlD
Tafluprost—PTGFR—uterus—breast cancer	0.00521	0.0398	CbGeAlD
Tafluprost—PTGFR—adipose tissue—breast cancer	0.0051	0.0389	CbGeAlD
Tafluprost—PTGFR—female reproductive system—breast cancer	0.00468	0.0357	CbGeAlD
Tafluprost—Carboprost Tromethamine—PTGER1—breast cancer	0.00459	0.312	CrCbGaD
Tafluprost—PTGFR—adrenal gland—breast cancer	0.00457	0.0349	CbGeAlD
Tafluprost—PTGFR—female gonad—breast cancer	0.00426	0.0325	CbGeAlD
Tafluprost—Common cold—Fluorouracil—breast cancer	0.00406	0.0285	CcSEcCtD
Tafluprost—PTGFR—endocrine gland—breast cancer	0.00396	0.0303	CbGeAlD
Tafluprost—Cataract—Toremifene—breast cancer	0.00308	0.0216	CcSEcCtD
Tafluprost—Iloprost—PTGER1—breast cancer	0.00296	0.201	CrCbGaD
Tafluprost—Punctate keratitis—Capecitabine—breast cancer	0.00293	0.0206	CcSEcCtD
Tafluprost—Bimatoprost—PTGER1—breast cancer	0.00288	0.196	CrCbGaD
Tafluprost—PTGFR—lymph node—breast cancer	0.00274	0.0209	CbGeAlD
Tafluprost—Dry eye—Toremifene—breast cancer	0.00271	0.019	CcSEcCtD
Tafluprost—Eye irritation—Letrozole—breast cancer	0.00268	0.0188	CcSEcCtD
Tafluprost—Lacrimation increased—Ixabepilone—breast cancer	0.00264	0.0185	CcSEcCtD
Tafluprost—Visual acuity reduced—Tamoxifen—breast cancer	0.00264	0.0185	CcSEcCtD
Tafluprost—Cataract—Anastrozole—breast cancer	0.00241	0.0169	CcSEcCtD
Tafluprost—Cataract—Letrozole—breast cancer	0.00241	0.0169	CcSEcCtD
Tafluprost—PTGS2—embryo—breast cancer	0.00212	0.0162	CbGeAlD
Tafluprost—Eye pruritus—Paclitaxel—breast cancer	0.00202	0.0142	CcSEcCtD
Tafluprost—Dinoprost Tromethamine—PTGER1—breast cancer	0.00175	0.119	CrCbGaD
Tafluprost—PTGS2—epithelium—breast cancer	0.00173	0.0132	CbGeAlD
Tafluprost—PTGS2—skin of body—breast cancer	0.00165	0.0126	CbGeAlD
Tafluprost—Cataract—Tamoxifen—breast cancer	0.00165	0.0116	CcSEcCtD
Tafluprost—Urinary tract infection—Fulvestrant—breast cancer	0.00161	0.0113	CcSEcCtD
Tafluprost—PTGS2—endometrium—breast cancer	0.00155	0.0119	CbGeAlD
Tafluprost—Visual acuity reduced—Paclitaxel—breast cancer	0.00152	0.0106	CcSEcCtD
Tafluprost—Photophobia—Vinblastine—breast cancer	0.00151	0.0106	CcSEcCtD
Tafluprost—PTGS2—uterus—breast cancer	0.00143	0.0109	CbGeAlD
Tafluprost—PTGS2—pituitary gland—breast cancer	0.00141	0.0107	CbGeAlD
Tafluprost—Urinary tract infection—Exemestane—breast cancer	0.0014	0.00984	CcSEcCtD
Tafluprost—PTGS2—adipose tissue—breast cancer	0.0014	0.0107	CbGeAlD
Tafluprost—Dry eye—Goserelin—breast cancer	0.00138	0.00971	CcSEcCtD
Tafluprost—Eye disorder—Toremifene—breast cancer	0.00137	0.00965	CcSEcCtD
Tafluprost—Iloprost—PDE4D—breast cancer	0.00137	0.0928	CrCbGaD
Tafluprost—Cataract—Thiotepa—breast cancer	0.00135	0.00945	CcSEcCtD
Tafluprost—Urinary tract infection—Ixabepilone—breast cancer	0.00132	0.00929	CcSEcCtD
Tafluprost—Rhinitis—Exemestane—breast cancer	0.0013	0.00911	CcSEcCtD
Tafluprost—PTGS2—female reproductive system—breast cancer	0.00129	0.00982	CbGeAlD
Tafluprost—PTGS2—adrenal gland—breast cancer	0.00126	0.00959	CbGeAlD
Tafluprost—Urinary tract infection—Anastrozole—breast cancer	0.00125	0.00875	CcSEcCtD
Tafluprost—Urinary tract infection—Letrozole—breast cancer	0.00125	0.00875	CcSEcCtD
Tafluprost—Visual acuity reduced—Capecitabine—breast cancer	0.00124	0.00874	CcSEcCtD
Tafluprost—Eye irritation—Fluorouracil—breast cancer	0.00124	0.00871	CcSEcCtD
Tafluprost—Cough—Lapatinib—breast cancer	0.00123	0.00865	CcSEcCtD
Tafluprost—PTGS2—bone marrow—breast cancer	0.00122	0.00927	CbGeAlD
Tafluprost—Vision blurred—Toremifene—breast cancer	0.00121	0.00848	CcSEcCtD
Tafluprost—Photophobia—Thiotepa—breast cancer	0.0012	0.00844	CcSEcCtD
Tafluprost—Lacrimation increased—Irinotecan—breast cancer	0.0012	0.00843	CcSEcCtD
Tafluprost—Dinoprost Tromethamine—HPGDS—breast cancer	0.00119	0.0806	CrCbGaD
Tafluprost—Urinary tract infection—Raloxifene—breast cancer	0.00118	0.0083	CcSEcCtD
Tafluprost—PTGS2—female gonad—breast cancer	0.00117	0.00894	CbGeAlD
Tafluprost—Rhinitis—Anastrozole—breast cancer	0.00115	0.0081	CcSEcCtD
Tafluprost—Lacrimation increased—Fluorouracil—breast cancer	0.00115	0.00807	CcSEcCtD
Tafluprost—Eye disorder—Ixabepilone—breast cancer	0.00114	0.00802	CcSEcCtD
Tafluprost—Cough—Fulvestrant—breast cancer	0.00113	0.00795	CcSEcCtD
Tafluprost—Nervous system disorder—Lapatinib—breast cancer	0.00113	0.00793	CcSEcCtD
Tafluprost—Rhinitis—Raloxifene—breast cancer	0.00109	0.00769	CcSEcCtD
Tafluprost—PTGS2—endocrine gland—breast cancer	0.00109	0.00831	CbGeAlD
Tafluprost—Eye disorder—Letrozole—breast cancer	0.00108	0.00755	CcSEcCtD
Tafluprost—Eye irritation—Paclitaxel—breast cancer	0.00106	0.00742	CcSEcCtD
Tafluprost—Nervous system disorder—Fulvestrant—breast cancer	0.00104	0.00729	CcSEcCtD
Tafluprost—Dyspnoea—Lapatinib—breast cancer	0.00103	0.00721	CcSEcCtD
Tafluprost—Nervous system disorder—Toremifene—breast cancer	0.00102	0.0072	CcSEcCtD
Tafluprost—Headache—Fluoxymesterone—breast cancer	0.00102	0.00714	CcSEcCtD
Tafluprost—Photophobia—Fluorouracil—breast cancer	0.000994	0.00698	CcSEcCtD
Tafluprost—Cough—Exemestane—breast cancer	0.000983	0.00691	CcSEcCtD
Tafluprost—Lacrimation increased—Paclitaxel—breast cancer	0.000979	0.00687	CcSEcCtD
Tafluprost—Dyspnoea—Fulvestrant—breast cancer	0.000944	0.00663	CcSEcCtD
Tafluprost—Vision blurred—Letrozole—breast cancer	0.000944	0.00663	CcSEcCtD
Tafluprost—Dyspnoea—Toremifene—breast cancer	0.000932	0.00654	CcSEcCtD
Tafluprost—Cough—Ixabepilone—breast cancer	0.000928	0.00652	CcSEcCtD
Tafluprost—Nervous system disorder—Exemestane—breast cancer	0.000902	0.00633	CcSEcCtD
Tafluprost—Eye irritation—Docetaxel—breast cancer	0.000895	0.00629	CcSEcCtD
Tafluprost—Cough—Letrozole—breast cancer	0.000874	0.00614	CcSEcCtD
Tafluprost—Cough—Anastrozole—breast cancer	0.000874	0.00614	CcSEcCtD
Tafluprost—Eye irritation—Capecitabine—breast cancer	0.000867	0.00609	CcSEcCtD
Tafluprost—Urinary tract infection—Tamoxifen—breast cancer	0.000852	0.00599	CcSEcCtD
Tafluprost—Nervous system disorder—Ixabepilone—breast cancer	0.000851	0.00598	CcSEcCtD
Tafluprost—Dry eye—Paclitaxel—breast cancer	0.000833	0.00585	CcSEcCtD
Tafluprost—Lacrimation increased—Docetaxel—breast cancer	0.00083	0.00583	CcSEcCtD
Tafluprost—Cough—Raloxifene—breast cancer	0.000829	0.00582	CcSEcCtD
Tafluprost—Dyspnoea—Exemestane—breast cancer	0.00082	0.00576	CcSEcCtD
Tafluprost—Pruritus—Lapatinib—breast cancer	0.000815	0.00572	CcSEcCtD
Tafluprost—Urinary tract infection—Goserelin—breast cancer	0.000814	0.00572	CcSEcCtD
Tafluprost—Lacrimation increased—Capecitabine—breast cancer	0.000803	0.00564	CcSEcCtD
Tafluprost—Nervous system disorder—Letrozole—breast cancer	0.000801	0.00563	CcSEcCtD
Tafluprost—Cataract—Capecitabine—breast cancer	0.000778	0.00546	CcSEcCtD
Tafluprost—Dyspnoea—Ixabepilone—breast cancer	0.000774	0.00543	CcSEcCtD
Tafluprost—Nervous system disorder—Raloxifene—breast cancer	0.000761	0.00534	CcSEcCtD
Tafluprost—Rhinitis—Goserelin—breast cancer	0.000754	0.00529	CcSEcCtD
Tafluprost—PTGS2—lymph node—breast cancer	0.000753	0.00575	CbGeAlD
Tafluprost—Pruritus—Fulvestrant—breast cancer	0.000749	0.00526	CcSEcCtD
Tafluprost—Pruritus—Toremifene—breast cancer	0.000739	0.00519	CcSEcCtD
Tafluprost—Dyspnoea—Anastrozole—breast cancer	0.000729	0.00512	CcSEcCtD
Tafluprost—Dyspnoea—Letrozole—breast cancer	0.000729	0.00512	CcSEcCtD
Tafluprost—Eye pain—Paclitaxel—breast cancer	0.000725	0.00509	CcSEcCtD
Tafluprost—Headache—Lapatinib—breast cancer	0.000721	0.00507	CcSEcCtD
Tafluprost—Eye disorder—Goserelin—breast cancer	0.000703	0.00493	CcSEcCtD
Tafluprost—Nasopharyngitis—Fluorouracil—breast cancer	0.000688	0.00483	CcSEcCtD
Tafluprost—Dry eye—Capecitabine—breast cancer	0.000684	0.0048	CcSEcCtD
Tafluprost—Headache—Fulvestrant—breast cancer	0.000663	0.00466	CcSEcCtD
Tafluprost—Headache—Toremifene—breast cancer	0.000655	0.0046	CcSEcCtD
Tafluprost—Pruritus—Exemestane—breast cancer	0.000651	0.00457	CcSEcCtD
Tafluprost—Vision blurred—Goserelin—breast cancer	0.000617	0.00433	CcSEcCtD
Tafluprost—Pruritus—Ixabepilone—breast cancer	0.000614	0.00431	CcSEcCtD
Tafluprost—Urinary tract infection—Mitoxantrone—breast cancer	0.000601	0.00422	CcSEcCtD
Tafluprost—Eye disorder—Thiotepa—breast cancer	0.000601	0.00422	CcSEcCtD
Tafluprost—Cough—Tamoxifen—breast cancer	0.000598	0.0042	CcSEcCtD
Tafluprost—Eye pain—Capecitabine—breast cancer	0.000595	0.00418	CcSEcCtD
Tafluprost—Cough—Melphalan—breast cancer	0.000586	0.00411	CcSEcCtD
Tafluprost—Nasopharyngitis—Paclitaxel—breast cancer	0.000585	0.00411	CcSEcCtD
Tafluprost—Pruritus—Letrozole—breast cancer	0.000578	0.00406	CcSEcCtD
Tafluprost—Pruritus—Anastrozole—breast cancer	0.000578	0.00406	CcSEcCtD
Tafluprost—Headache—Exemestane—breast cancer	0.000576	0.00405	CcSEcCtD
Tafluprost—Urinary tract infection—Fluorouracil—breast cancer	0.000576	0.00404	CcSEcCtD
Tafluprost—Cough—Goserelin—breast cancer	0.000571	0.00401	CcSEcCtD
Tafluprost—Lacrimation increased—Epirubicin—breast cancer	0.00056	0.00393	CcSEcCtD
Tafluprost—Rhinitis—Irinotecan—breast cancer	0.000557	0.00391	CcSEcCtD
Tafluprost—Rhinitis—Mitoxantrone—breast cancer	0.000557	0.00391	CcSEcCtD
Tafluprost—Headache—Ixabepilone—breast cancer	0.000544	0.00382	CcSEcCtD
Tafluprost—Rhinitis—Gemcitabine—breast cancer	0.000542	0.00381	CcSEcCtD
Tafluprost—Rhinitis—Fluorouracil—breast cancer	0.000533	0.00374	CcSEcCtD
Tafluprost—Vision blurred—Thiotepa—breast cancer	0.000528	0.00371	CcSEcCtD
Tafluprost—Nervous system disorder—Goserelin—breast cancer	0.000524	0.00368	CcSEcCtD
Tafluprost—Lacrimation increased—Doxorubicin—breast cancer	0.000518	0.00364	CcSEcCtD
Tafluprost—Headache—Letrozole—breast cancer	0.000512	0.0036	CcSEcCtD
Tafluprost—Headache—Anastrozole—breast cancer	0.000512	0.0036	CcSEcCtD
Tafluprost—Cough—Vinorelbine—breast cancer	0.000512	0.00359	CcSEcCtD
Tafluprost—Dyspnoea—Tamoxifen—breast cancer	0.000499	0.0035	CcSEcCtD
Tafluprost—Nasopharyngitis—Docetaxel—breast cancer	0.000496	0.00348	CcSEcCtD
Tafluprost—Urinary tract infection—Paclitaxel—breast cancer	0.00049	0.00344	CcSEcCtD
Tafluprost—Cough—Thiotepa—breast cancer	0.000489	0.00343	CcSEcCtD
Tafluprost—Dyspnoea—Melphalan—breast cancer	0.000488	0.00343	CcSEcCtD
Tafluprost—Headache—Raloxifene—breast cancer	0.000486	0.00341	CcSEcCtD
Tafluprost—Headache—Idarubicin—breast cancer	0.000486	0.00341	CcSEcCtD
Tafluprost—Nasopharyngitis—Capecitabine—breast cancer	0.00048	0.00337	CcSEcCtD
Tafluprost—Dry eye—Epirubicin—breast cancer	0.000476	0.00334	CcSEcCtD
Tafluprost—Dyspnoea—Goserelin—breast cancer	0.000476	0.00334	CcSEcCtD
Tafluprost—Nervous system disorder—Vinorelbine—breast cancer	0.000469	0.00329	CcSEcCtD
Tafluprost—Asthma—Capecitabine—breast cancer	0.000464	0.00326	CcSEcCtD
Tafluprost—Vision blurred—Mitoxantrone—breast cancer	0.000456	0.0032	CcSEcCtD
Tafluprost—Rhinitis—Paclitaxel—breast cancer	0.000454	0.00319	CcSEcCtD
Tafluprost—Nervous system disorder—Thiotepa—breast cancer	0.000448	0.00315	CcSEcCtD
Tafluprost—Pruritus—Chlorambucil—breast cancer	0.000444	0.00312	CcSEcCtD
Tafluprost—Dry eye—Doxorubicin—breast cancer	0.000441	0.00309	CcSEcCtD
Tafluprost—Vision blurred—Fluorouracil—breast cancer	0.000436	0.00306	CcSEcCtD
Tafluprost—Dyspnoea—Vinorelbine—breast cancer	0.000427	0.003	CcSEcCtD
Tafluprost—Eye disorder—Paclitaxel—breast cancer	0.000423	0.00297	CcSEcCtD
Tafluprost—Cough—Irinotecan—breast cancer	0.000422	0.00296	CcSEcCtD
Tafluprost—Cough—Mitoxantrone—breast cancer	0.000422	0.00296	CcSEcCtD
Tafluprost—Eye pain—Epirubicin—breast cancer	0.000415	0.00291	CcSEcCtD
Tafluprost—Cough—Gemcitabine—breast cancer	0.000411	0.00289	CcSEcCtD
Tafluprost—Urinary tract infection—Capecitabine—breast cancer	0.000402	0.00283	CcSEcCtD
Tafluprost—Pruritus—Tamoxifen—breast cancer	0.000396	0.00278	CcSEcCtD
Tafluprost—Pruritus—Melphalan—breast cancer	0.000387	0.00272	CcSEcCtD
Tafluprost—Nervous system disorder—Irinotecan—breast cancer	0.000387	0.00272	CcSEcCtD
Tafluprost—Rhinitis—Docetaxel—breast cancer	0.000385	0.0027	CcSEcCtD
Tafluprost—Eye pain—Doxorubicin—breast cancer	0.000384	0.00269	CcSEcCtD
Tafluprost—Pruritus—Goserelin—breast cancer	0.000378	0.00265	CcSEcCtD
Tafluprost—Nervous system disorder—Gemcitabine—breast cancer	0.000377	0.00265	CcSEcCtD
Tafluprost—Rhinitis—Capecitabine—breast cancer	0.000373	0.00262	CcSEcCtD
Tafluprost—Vision blurred—Paclitaxel—breast cancer	0.000372	0.00261	CcSEcCtD
Tafluprost—Nervous system disorder—Fluorouracil—breast cancer	0.000371	0.0026	CcSEcCtD
Tafluprost—Headache—Vinblastine—breast cancer	0.000361	0.00253	CcSEcCtD
Tafluprost—Eye disorder—Docetaxel—breast cancer	0.000359	0.00252	CcSEcCtD
Tafluprost—Dyspnoea—Mitoxantrone—breast cancer	0.000352	0.00247	CcSEcCtD
Tafluprost—Dyspnoea—Irinotecan—breast cancer	0.000352	0.00247	CcSEcCtD
Tafluprost—Headache—Tamoxifen—breast cancer	0.00035	0.00246	CcSEcCtD
Tafluprost—Eye disorder—Capecitabine—breast cancer	0.000347	0.00244	CcSEcCtD
Tafluprost—Asthma—Methotrexate—breast cancer	0.000346	0.00243	CcSEcCtD
Tafluprost—Cough—Paclitaxel—breast cancer	0.000344	0.00242	CcSEcCtD
Tafluprost—Dyspnoea—Gemcitabine—breast cancer	0.000343	0.00241	CcSEcCtD
Tafluprost—Pruritus—Vinorelbine—breast cancer	0.000338	0.00238	CcSEcCtD
Tafluprost—Dyspnoea—Fluorouracil—breast cancer	0.000337	0.00237	CcSEcCtD
Tafluprost—Nasopharyngitis—Epirubicin—breast cancer	0.000335	0.00235	CcSEcCtD
Tafluprost—Headache—Goserelin—breast cancer	0.000335	0.00235	CcSEcCtD
Tafluprost—Asthma—Epirubicin—breast cancer	0.000324	0.00227	CcSEcCtD
Tafluprost—Pruritus—Thiotepa—breast cancer	0.000323	0.00227	CcSEcCtD
Tafluprost—Nervous system disorder—Paclitaxel—breast cancer	0.000316	0.00222	CcSEcCtD
Tafluprost—Nasopharyngitis—Doxorubicin—breast cancer	0.00031	0.00217	CcSEcCtD
Tafluprost—Vision blurred—Capecitabine—breast cancer	0.000305	0.00214	CcSEcCtD
Tafluprost—Headache—Vinorelbine—breast cancer	0.0003	0.0021	CcSEcCtD
Tafluprost—Asthma—Doxorubicin—breast cancer	0.000299	0.0021	CcSEcCtD
Tafluprost—Cough—Docetaxel—breast cancer	0.000292	0.00205	CcSEcCtD
Tafluprost—Dyspnoea—Paclitaxel—breast cancer	0.000287	0.00201	CcSEcCtD
Tafluprost—Headache—Thiotepa—breast cancer	0.000286	0.00201	CcSEcCtD
Tafluprost—Cough—Capecitabine—breast cancer	0.000282	0.00198	CcSEcCtD
Tafluprost—Urinary tract infection—Epirubicin—breast cancer	0.00028	0.00197	CcSEcCtD
Tafluprost—Pruritus—Gemcitabine—breast cancer	0.000272	0.00191	CcSEcCtD
Tafluprost—Nervous system disorder—Docetaxel—breast cancer	0.000267	0.00188	CcSEcCtD
Tafluprost—Pruritus—Fluorouracil—breast cancer	0.000267	0.00188	CcSEcCtD
Tafluprost—Rhinitis—Epirubicin—breast cancer	0.00026	0.00182	CcSEcCtD
Tafluprost—Urinary tract infection—Doxorubicin—breast cancer	0.000259	0.00182	CcSEcCtD
Tafluprost—Nervous system disorder—Capecitabine—breast cancer	0.000259	0.00182	CcSEcCtD
Tafluprost—Eye disorder—Methotrexate—breast cancer	0.000259	0.00182	CcSEcCtD
Tafluprost—Headache—Mitoxantrone—breast cancer	0.000247	0.00174	CcSEcCtD
Tafluprost—Headache—Irinotecan—breast cancer	0.000247	0.00174	CcSEcCtD
Tafluprost—Dyspnoea—Docetaxel—breast cancer	0.000243	0.00171	CcSEcCtD
Tafluprost—Eye disorder—Epirubicin—breast cancer	0.000242	0.0017	CcSEcCtD
Tafluprost—Headache—Gemcitabine—breast cancer	0.000241	0.00169	CcSEcCtD
Tafluprost—Rhinitis—Doxorubicin—breast cancer	0.00024	0.00169	CcSEcCtD
Tafluprost—Headache—Fluorouracil—breast cancer	0.000237	0.00166	CcSEcCtD
Tafluprost—Dyspnoea—Capecitabine—breast cancer	0.000235	0.00165	CcSEcCtD
Tafluprost—Pruritus—Paclitaxel—breast cancer	0.000228	0.0016	CcSEcCtD
Tafluprost—Vision blurred—Methotrexate—breast cancer	0.000227	0.00159	CcSEcCtD
Tafluprost—Eye disorder—Doxorubicin—breast cancer	0.000224	0.00157	CcSEcCtD
Tafluprost—Vision blurred—Epirubicin—breast cancer	0.000212	0.00149	CcSEcCtD
Tafluprost—Cough—Methotrexate—breast cancer	0.00021	0.00148	CcSEcCtD
Tafluprost—Headache—Paclitaxel—breast cancer	0.000202	0.00142	CcSEcCtD
Tafluprost—Cough—Epirubicin—breast cancer	0.000197	0.00138	CcSEcCtD
Tafluprost—Vision blurred—Doxorubicin—breast cancer	0.000197	0.00138	CcSEcCtD
Tafluprost—Pruritus—Docetaxel—breast cancer	0.000193	0.00136	CcSEcCtD
Tafluprost—Nervous system disorder—Methotrexate—breast cancer	0.000193	0.00135	CcSEcCtD
Tafluprost—Pruritus—Capecitabine—breast cancer	0.000187	0.00131	CcSEcCtD
Tafluprost—Cough—Doxorubicin—breast cancer	0.000182	0.00128	CcSEcCtD
Tafluprost—Nervous system disorder—Epirubicin—breast cancer	0.00018	0.00127	CcSEcCtD
Tafluprost—Dyspnoea—Methotrexate—breast cancer	0.000175	0.00123	CcSEcCtD
Tafluprost—Headache—Docetaxel—breast cancer	0.000171	0.0012	CcSEcCtD
Tafluprost—Nervous system disorder—Doxorubicin—breast cancer	0.000167	0.00117	CcSEcCtD
Tafluprost—Headache—Capecitabine—breast cancer	0.000165	0.00116	CcSEcCtD
Tafluprost—Dyspnoea—Epirubicin—breast cancer	0.000164	0.00115	CcSEcCtD
Tafluprost—Dyspnoea—Doxorubicin—breast cancer	0.000152	0.00107	CcSEcCtD
Tafluprost—Pruritus—Methotrexate—breast cancer	0.000139	0.000977	CcSEcCtD
Tafluprost—Pruritus—Epirubicin—breast cancer	0.00013	0.000914	CcSEcCtD
Tafluprost—Headache—Methotrexate—breast cancer	0.000123	0.000865	CcSEcCtD
Tafluprost—Pruritus—Doxorubicin—breast cancer	0.00012	0.000846	CcSEcCtD
Tafluprost—Headache—Epirubicin—breast cancer	0.000115	0.000809	CcSEcCtD
Tafluprost—Headache—Doxorubicin—breast cancer	0.000107	0.000749	CcSEcCtD
Tafluprost—PTGS2—Metabolism—ADSL—breast cancer	5.32e-05	0.000283	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—UMPS—breast cancer	5.32e-05	0.000283	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PHGDH—breast cancer	5.32e-05	0.000283	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—FHL2—breast cancer	5.32e-05	0.000283	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NME1—breast cancer	5.32e-05	0.000283	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGF1—breast cancer	5.27e-05	0.00028	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CSF2—breast cancer	5.27e-05	0.00028	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—RAF1—breast cancer	5.25e-05	0.000279	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRG1—breast cancer	5.23e-05	0.000278	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HPSE—breast cancer	5.22e-05	0.000278	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—BRIP1—breast cancer	5.22e-05	0.000278	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LDHB—breast cancer	5.22e-05	0.000278	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HEY2—breast cancer	5.2e-05	0.000277	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—H2AFX—breast cancer	5.19e-05	0.000276	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IL2—breast cancer	5.19e-05	0.000276	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—E2F1—breast cancer	5.15e-05	0.000274	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPS6KB2—breast cancer	5.14e-05	0.000273	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CB—breast cancer	5.13e-05	0.000273	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—breast cancer	5.1e-05	0.000271	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IDH1—breast cancer	5.08e-05	0.00027	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—breast cancer	5.05e-05	0.000268	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—breast cancer	4.96e-05	0.000264	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SPP1—breast cancer	4.95e-05	0.000263	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTA3—breast cancer	4.95e-05	0.000263	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCC1—breast cancer	4.95e-05	0.000263	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HMMR—breast cancer	4.95e-05	0.000263	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL8—breast cancer	4.93e-05	0.000262	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ERBB3—breast cancer	4.9e-05	0.00026	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGFR2—breast cancer	4.89e-05	0.00026	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TLE3—breast cancer	4.87e-05	0.000259	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HEY1—breast cancer	4.82e-05	0.000256	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARGC1B—breast cancer	4.79e-05	0.000255	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPL23A—breast cancer	4.72e-05	0.000251	CbGpPWpGaD
Tafluprost—PTGS2—Disease—DLL1—breast cancer	4.72e-05	0.000251	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL2—breast cancer	4.71e-05	0.00025	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—breast cancer	4.69e-05	0.00025	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TERT—breast cancer	4.69e-05	0.000249	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	4.67e-05	0.000248	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	4.67e-05	0.000248	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIST1H2BC—breast cancer	4.64e-05	0.000247	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MAP2K7—breast cancer	4.64e-05	0.000247	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIST1H2BK—breast cancer	4.64e-05	0.000247	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—breast cancer	4.57e-05	0.000243	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGFR1—breast cancer	4.56e-05	0.000242	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—breast cancer	4.56e-05	0.000242	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTA4—breast cancer	4.53e-05	0.000241	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CA9—breast cancer	4.53e-05	0.000241	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HIF1A—breast cancer	4.49e-05	0.000239	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—GPX1—breast cancer	4.47e-05	0.000238	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—breast cancer	4.47e-05	0.000237	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	4.42e-05	0.000235	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPX2—breast cancer	4.41e-05	0.000234	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTA2—breast cancer	4.41e-05	0.000234	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPS7—breast cancer	4.41e-05	0.000234	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPS8—breast cancer	4.41e-05	0.000234	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LEP—breast cancer	4.38e-05	0.000233	CbGpPWpGaD
Tafluprost—PTGS2—Disease—DKK1—breast cancer	4.37e-05	0.000232	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SULT1A1—breast cancer	4.36e-05	0.000232	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPX4—breast cancer	4.36e-05	0.000232	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CAV1—breast cancer	4.34e-05	0.000231	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ALDOA—breast cancer	4.34e-05	0.000231	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KDR—breast cancer	4.29e-05	0.000228	CbGpPWpGaD
Tafluprost—PTGS2—Disease—JAG2—breast cancer	4.27e-05	0.000227	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTA1—breast cancer	4.26e-05	0.000226	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—IDH1—breast cancer	4.26e-05	0.000226	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	4.25e-05	0.000226	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	4.22e-05	0.000224	CbGpPWpGaD
Tafluprost—PTGS2—Disease—WNT1—breast cancer	4.21e-05	0.000224	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NAT2—breast cancer	4.21e-05	0.000224	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ESR1—breast cancer	4.18e-05	0.000222	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC2A2—breast cancer	4.18e-05	0.000222	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FN1—breast cancer	4.13e-05	0.00022	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTR—breast cancer	4.1e-05	0.000218	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NFKBIA—breast cancer	4.08e-05	0.000217	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH1—breast cancer	4.04e-05	0.000215	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KIT—breast cancer	3.95e-05	0.00021	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CG—breast cancer	3.95e-05	0.00021	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APC—breast cancer	3.95e-05	0.00021	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGF—breast cancer	3.91e-05	0.000208	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	3.88e-05	0.000206	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HSPA1B—breast cancer	3.81e-05	0.000202	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	3.8e-05	0.000202	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MAPK3—breast cancer	3.79e-05	0.000201	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	3.75e-05	0.000199	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—BRAF—breast cancer	3.72e-05	0.000198	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—DPYD—breast cancer	3.69e-05	0.000196	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MED12—breast cancer	3.69e-05	0.000196	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ENO1—breast cancer	3.65e-05	0.000194	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALDOA—breast cancer	3.63e-05	0.000193	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IGF1—breast cancer	3.62e-05	0.000192	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT2—breast cancer	3.62e-05	0.000192	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EGFR—breast cancer	3.6e-05	0.000192	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NCOA3—breast cancer	3.53e-05	0.000187	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC2A2—breast cancer	3.5e-05	0.000186	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CD—breast cancer	3.48e-05	0.000185	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	3.47e-05	0.000184	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGF3—breast cancer	3.45e-05	0.000184	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CA—breast cancer	3.44e-05	0.000183	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SERPINE1—breast cancer	3.44e-05	0.000183	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCG2—breast cancer	3.43e-05	0.000182	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CPT1A—breast cancer	3.43e-05	0.000182	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MTR—breast cancer	3.43e-05	0.000182	CbGpPWpGaD
Tafluprost—PTGS2—Disease—JAG1—breast cancer	3.41e-05	0.000181	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FASN—breast cancer	3.41e-05	0.000181	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—KRAS—breast cancer	3.4e-05	0.000181	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PARP1—breast cancer	3.39e-05	0.00018	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HPGDS—breast cancer	3.36e-05	0.000179	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CALCA—breast cancer	3.35e-05	0.000178	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HBA1—breast cancer	3.34e-05	0.000178	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPS6—breast cancer	3.31e-05	0.000176	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGF4—breast cancer	3.29e-05	0.000175	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOS3—breast cancer	3.28e-05	0.000175	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CXCR4—breast cancer	3.27e-05	0.000174	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTT1—breast cancer	3.26e-05	0.000173	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ACHE—breast cancer	3.26e-05	0.000173	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC2A1—breast cancer	3.24e-05	0.000172	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	3.17e-05	0.000168	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TCF7L2—breast cancer	3.16e-05	0.000168	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CA—breast cancer	3.13e-05	0.000166	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MDM2—breast cancer	3.11e-05	0.000166	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RAF1—breast cancer	3.1e-05	0.000165	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RELA—breast cancer	3.09e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP17A1—breast cancer	3.09e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ERBB2—breast cancer	3.07e-05	0.000163	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTGS1—breast cancer	3.06e-05	0.000163	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ENO1—breast cancer	3.06e-05	0.000163	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	3.05e-05	0.000162	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HSP90AA1—breast cancer	3.04e-05	0.000162	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CB—breast cancer	3.03e-05	0.000161	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MTOR—breast cancer	3.03e-05	0.000161	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALB—breast cancer	3.01e-05	0.00016	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP2D6—breast cancer	3e-05	0.000159	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PRL—breast cancer	2.96e-05	0.000157	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NCOA2—breast cancer	2.94e-05	0.000156	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ADAM10—breast cancer	2.92e-05	0.000155	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL8—breast cancer	2.91e-05	0.000155	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—HRAS—breast cancer	2.89e-05	0.000154	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—FASN—breast cancer	2.85e-05	0.000152	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CDKN1B—breast cancer	2.84e-05	0.000151	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—BCHE—breast cancer	2.84e-05	0.000151	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGF10—breast cancer	2.84e-05	0.000151	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKT1—breast cancer	2.81e-05	0.00015	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC5A5—breast cancer	2.81e-05	0.000149	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CASP3—breast cancer	2.79e-05	0.000148	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL2—breast cancer	2.78e-05	0.000148	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—breast cancer	2.77e-05	0.000147	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PDGFA—breast cancer	2.74e-05	0.000146	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCND1—breast cancer	2.71e-05	0.000144	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC2A1—breast cancer	2.71e-05	0.000144	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NQO1—breast cancer	2.71e-05	0.000144	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—JUN—breast cancer	2.71e-05	0.000144	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFBR2—breast cancer	2.7e-05	0.000144	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CTNNB1—breast cancer	2.69e-05	0.000143	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ITPR1—breast cancer	2.66e-05	0.000141	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	2.66e-05	0.000141	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP3A4—breast cancer	2.64e-05	0.000141	CbGpPWpGaD
Tafluprost—PTGS2—Disease—STAT5A—breast cancer	2.64e-05	0.00014	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERBB4—breast cancer	2.64e-05	0.00014	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP9—breast cancer	2.63e-05	0.00014	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CDKN1A—breast cancer	2.62e-05	0.00014	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTEN—breast cancer	2.62e-05	0.000139	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP1B1—breast cancer	2.6e-05	0.000138	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK8—breast cancer	2.56e-05	0.000136	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SMAD4—breast cancer	2.56e-05	0.000136	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKT1—breast cancer	2.55e-05	0.000136	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HSP90AA1—breast cancer	2.55e-05	0.000136	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HES1—breast cancer	2.5e-05	0.000133	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NCOR1—breast cancer	2.48e-05	0.000132	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NCOA1—breast cancer	2.48e-05	0.000132	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGF1—breast cancer	2.45e-05	0.00013	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—STK11—breast cancer	2.44e-05	0.00013	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP19A1—breast cancer	2.44e-05	0.00013	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NRG1—breast cancer	2.44e-05	0.000129	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SRC—breast cancer	2.43e-05	0.000129	CbGpPWpGaD
Tafluprost—PTGS2—Disease—H2AFX—breast cancer	2.42e-05	0.000129	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—VEGFA—breast cancer	2.36e-05	0.000126	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—STAT3—breast cancer	2.34e-05	0.000124	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERCC2—breast cancer	2.33e-05	0.000124	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.29e-05	0.000122	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERBB3—breast cancer	2.28e-05	0.000121	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGFR2—breast cancer	2.28e-05	0.000121	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—COMT—breast cancer	2.27e-05	0.000121	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTP1—breast cancer	2.26e-05	0.00012	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK3—breast cancer	2.24e-05	0.000119	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HMOX1—breast cancer	2.23e-05	0.000119	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ITPR1—breast cancer	2.23e-05	0.000118	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTHFR—breast cancer	2.19e-05	0.000117	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TERT—breast cancer	2.19e-05	0.000116	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—breast cancer	2.18e-05	0.000116	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TGFB1—breast cancer	2.17e-05	0.000115	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCB1—breast cancer	2.14e-05	0.000114	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGFR—breast cancer	2.13e-05	0.000113	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGFR1—breast cancer	2.12e-05	0.000113	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMS—breast cancer	2.1e-05	0.000112	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIF1A—breast cancer	2.09e-05	0.000111	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PLA2G4A—breast cancer	2.08e-05	0.00011	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTM1—breast cancer	2.08e-05	0.00011	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NCOR1—breast cancer	2.08e-05	0.00011	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CAV1—breast cancer	2.02e-05	0.000108	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KRAS—breast cancer	2.01e-05	0.000107	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPX1—breast cancer	1.99e-05	0.000106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP1A1—breast cancer	1.97e-05	0.000105	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ERCC2—breast cancer	1.95e-05	0.000104	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOS2—breast cancer	1.9e-05	0.000101	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOTCH1—breast cancer	1.88e-05	0.0001	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CA—breast cancer	1.85e-05	9.82e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APC—breast cancer	1.84e-05	9.8e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KIT—breast cancer	1.84e-05	9.8e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MTHFR—breast cancer	1.84e-05	9.76e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGF—breast cancer	1.82e-05	9.68e-05	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TP53—breast cancer	1.79e-05	9.5e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—BRAF—breast cancer	1.73e-05	9.21e-05	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HRAS—breast cancer	1.71e-05	9.08e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CAV1—breast cancer	1.69e-05	9.01e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT2—breast cancer	1.69e-05	8.96e-05	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—breast cancer	1.64e-05	8.69e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CD—breast cancer	1.62e-05	8.61e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.62e-05	8.6e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SERPINE1—breast cancer	1.6e-05	8.52e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CG—breast cancer	1.54e-05	8.2e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOS3—breast cancer	1.53e-05	8.13e-05	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT1—breast cancer	1.51e-05	8.02e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MDM2—breast cancer	1.45e-05	7.71e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RAF1—breast cancer	1.45e-05	7.69e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERBB2—breast cancer	1.43e-05	7.61e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CB—breast cancer	1.41e-05	7.51e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTOR—breast cancer	1.41e-05	7.51e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD4—breast cancer	1.41e-05	7.49e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CD—breast cancer	1.36e-05	7.21e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALB—breast cancer	1.34e-05	7.12e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CDKN1B—breast cancer	1.33e-05	7.04e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NOS3—breast cancer	1.28e-05	6.81e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CTNNB1—breast cancer	1.25e-05	6.65e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CDKN1A—breast cancer	1.22e-05	6.5e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PTEN—breast cancer	1.22e-05	6.49e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CB—breast cancer	1.18e-05	6.29e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SRC—breast cancer	1.13e-05	6.01e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—STAT3—breast cancer	1.09e-05	5.8e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MAPK3—breast cancer	1.04e-05	5.54e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTEN—breast cancer	1.02e-05	5.43e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—breast cancer	1.01e-05	5.39e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFB1—breast cancer	1.01e-05	5.38e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGFR—breast cancer	9.92e-06	5.27e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KRAS—breast cancer	9.37e-06	4.98e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CA—breast cancer	8.61e-06	4.58e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HRAS—breast cancer	7.96e-06	4.23e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—breast cancer	7.62e-06	4.05e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CA—breast cancer	7.21e-06	3.83e-05	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT1—breast cancer	7.03e-06	3.74e-05	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKT1—breast cancer	5.89e-06	3.13e-05	CbGpPWpGaD
